NEOSTIGMINE

category:
153
CALCUTIONS AREA
CLICK ON CALCULATOR

Infant Data

Results

MEDICAL INFORMATIONS

INDICATIONS

  • Neonatal transient myasthenia gravis.
  • Neonatal persistent (congenital) myasthenia gravis.

FDA APPROVED INDICATION

Reversal of neuromuscular blocking agents

CONTRAINDICATION

Contraindicated in the presence of intestinal or urinary obstruction or in the presence of peritonitis.

CONTRAINDICATION

  • Use cautiously in patients with bronchospasm, cardiac arrhythmia, hypotension, or bradycardia
  • Large doses may cause neuromuscular dysfunction in patients with minimal blockade; dose reduction recommended if recovery from neuromuscular blockade is nearly complete .

ADVERSE EFFECTS

Adverse effects include muscle weakness, tremors, bradycardia, hypotension, respiratory depression, bronchospasm, diarrhea, and excessive salivation.

ADMINISTRATION

Administer IV over at least 1 minute. Give with atropine or glycopyrrolate to prevent possible bradycardia, increased salivation, and hyperperistalsis . For myasthenia gravis diagnosis, test dose is given IM .

MONITORING

  • Monitor respiratory and cardiovascular status closely .
  • Train-of-four monitoring should used to evaluate recovery of neuromuscular blockade